← Back to Search

Antibiotic

Diagnostic Testing for Cephalosporin Allergy (DACAT Trial)

Phase 2
Waitlist Available
Led By Kimberly G Blumenthal, MD, MSc
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18-70 years old
Be older than 18 years old
Must not have
Severe concomitant medical condition (e.g., unstable coronary artery disease, congestive heart failure, severe chronic obstructive pulmonary disease, poorly controlled asthma, chronic renal failure, cirrhosis, or end-stage liver disease)
Abnormal vital signs or unstable physical exam at Visit 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 54 months
Awards & highlights

Summary

"This trial aims to improve the way we diagnose and manage allergic reactions to cephalosporin antibiotics, which can be severe. The study will explore new methods to better understand and treat these allergies."

Who is the study for?
This trial is for individuals who have had allergic reactions or anaphylaxis to cephalosporin antibiotics. Participants should not currently be on beta-lactam antibiotics and must have a history of immediate reaction to at least one cephalosporin.
What is being tested?
The study tests the safety and effectiveness of various cephalosporins through skin testing and controlled drug challenges, aiming to improve diagnostic methods for those with suspected cephalosporin allergies.
What are the potential side effects?
Potential side effects may include allergic reactions ranging from mild skin irritation to more severe responses like anaphylaxis, which would require immediate medical attention.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 70 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have severe heart, lung, kidney, or liver conditions.
Select...
My vital signs were not normal or I was physically unstable during my first visit.
Select...
I needed CPR due to a severe reaction.
Select...
I have had a Clostridioides difficile infection before.
Select...
I haven't taken antihistamines or steroids in the last week.
Select...
I have not taken omalizumab or dupilumab in the last 60 days.
Select...
I have not had an infection or taken antibiotics in the last week.
Select...
I have taken a beta-blocker or ACE inhibitor in the last week.
Select...
I have chronic hives or systemic mastocytosis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 54 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 54 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cephalosporin skin test sensitivity and specificity
Proportion of cross-reactivity to other cephalosporins in confirmed-allergic subjects
Proportion of participants with confirmed culprit cephalosporin allergy
Secondary study objectives
Association between patient allergy history and confirmed cephalosporin allergy
Association between patient demographics and confirmed cephalosporin allergy
Cephalosporin skin test diagnostic characteristic performance differences between risk groups
+4 more
Other study objectives
Amoxicillin cross-reactivity in those with confirmed cephalosporin allergy
Amoxicillin skin test diagnostic characteristics in those with confirmed cephalosporin allergy
Cephalosporin skin test clinical statistics
+8 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Similar cephalosporin firstExperimental Treatment5 Interventions
In visit 2, confirmed-allergic subjects will have a double-blind placebo-controlled drug challenge to a similar side chain cephalosporin, followed by a double-blind placebo-controlled challenge to a dissimilar side chain cephalosporin in visit 3. The randomization of which cephalosporin (similar or dissimilar side chain) is challenged in visits 2 and 3 differentiates the two arms.
Group II: Dissimilar cephalosporin firstExperimental Treatment5 Interventions
In visit 2, confirmed-allergic subjects will have a double-blind placebo-controlled drug challenge to a dissimilar side chain cephalosporin, followed by a double-blind placebo-controlled challenge to a similar side chain cephalosporin in visit 3. The randomization of which cephalosporin (similar or dissimilar side chain) is challenged in visits 2 and 3 differentiates the two arms.

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,993 Previous Clinical Trials
13,230,421 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,302 Previous Clinical Trials
5,501,142 Total Patients Enrolled
Kimberly G Blumenthal, MD, MScPrincipal InvestigatorMassachusetts General Hospital
~200 spots leftby Jul 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top